P-003

P-003 is a pharmaceutical candidate currently in development by Pangea Pharmaceuticals, specifically targeting the treatment of pain and inflammation. Pangea Pharmaceuticals is a specialty pharmaceutical company that primarily focuses on the development of reformulated or generic versions of existing drugs, often utilizing the 505(b)(2) regulatory pathway to improve upon established therapies. While the specific active ingredient for P-003 has not been publicly disclosed in the company's pipeline summaries, its therapeutic focus suggests it is likely a small molecule nonsteroidal anti-inflammatory drug (NSAID) or a related analgesic. The drug is part of a broader pipeline of pain management therapies being advanced by the company, with an estimated launch timeframe projected for 2025.